Buy Bausch Health

Logo for stock BHC (Bausch Health)

Amount

£
GBP

Latest price

$5.661
(£1.00 = $1.328)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$2.918B

P/E ratio

30.01

EPS

$0.263

Beta

0.43

Dividend rate

N/A

Dividend yield

N/A

About

Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter (OTC) products and ophthalmic surgical devices and instruments. The Salix segment consists of sales in the U.S. of gastroenterology products. The International segment consists of sales, except for sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Diversified segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Bausch + Lomb segment includes Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.

CEO

Mr. Thomas J. Appio

Employees

20,700

Sector

Health

Company HQ

LAVAL, Canada

News

Logo for news article #0 (Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat)

Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat

BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.

Zacks Investment Research

July 31, 2025

Logo for news article #1 (Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript)

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC ) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executive VP & CFO Thomas J. Appio - CEO & Director Conference Call Participants Douglas Miehm - RBC Capital Markets, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Operator Welcome to the Bausch Health First Quarter 2025 Earnings Call.

Seeking Alpha

July 31, 2025

Logo for news article #2 (Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say)

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research

July 31, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.